Loading company
Candel Therapeutics, Inc.
CADL · Nasdaq · ·
$10.88-2.9%Sep 29 close
- 1M
- -16.8%
- 6M
- +142.9%
- 1Y
- +113.3%
- 5Y
- +5.9%
CADL · Nasdaq · ·
$10.88-2.9%Sep 29 close
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toDec 31, 2021 | Change |
|---|---|---|---|
| Total Revenue | $31K | $31K | 0.00% |
| Profit | -$38.9M | -$4.8M | -711.20% |
| Profit per share | -$0.52 | -$0.09 | -477.78% |
| Free Cash Flow | -$17.3M | -$8.9M | -93.35% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Candel Therapeutics, Inc. has no earnings call transcript available.
“This quarter reflects meaningful execution across the company as we advance aglatimagene toward a planned BLA submission in the fourth quarter of 2026 and continue to build the foundation for a potential U.S. commercial launch in localized prostate cancer,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Candel Therapeutics, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.